Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Increasingly, medicines research is moving from ‘big pharma’ to small biotech companies and start-ups. To succeed in this new environment, scientific skills are not enough employers and financiers also need to be confident that the people they are working with possess the entrepreneurial skills to grow and sustain a business effectively. Pharmaceutical formulation development enables development of robust and compliant formulations and resolve difficult challenges encountered during pre-clinical and clinical development.
  • Track 1-1. Pre-Formulation and Formulation Aspects
  • Track 1-2. Pre-formulation in Drug Development
  • Track 1-3. Major Challenges in Drug Development
Particle Sciences has a great deal of successful experience in the development of successful delivery systems for many types of APIs and sites of action. Drug delivery technologies enhance drug absorption, efficacy, and patient experience. Enhancing the drug delivery technology of final pharmaceutical formulation can increase its commercial success. Drug delivery systems have been used in delaying drug clearance processes. Drug delivery approaches have their advantages and limitations. Drug delivery approaches include solubilization, permeability enhancement, modified release (MR). The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. The North American drug delivery technologies market is projected to reach USD 758.7 Billion by 2021 from USD 520.0 Billion in 2016, at a CAGR of 6.5% during the forecast period.
  • Track 2-1. Self-microemulsifying drug delivery systems SMEDDSs
  • Track 2-2. Liposomes Drug Delivery Systems
  • Track 2-3. Hydrogels drug delivery
  • Track 2-4. Microspheres drug delivery
  • Track 2-5. Solid Dispersion
  • Track 2-6. Dynamic invitro-invivo studies
  • Track 2-7. Osmotics Micro Pumps
  • Track 2-8. Micronization Techniques
  • Track 2-9. PH and Temperature sensitive
  • Track 2-10. Controlled Drug Delivery Systems
  • Track 2-11. Micro and Nano Technology
  • Track 2-12. Drug Release Testing
Drug delivery systems control the pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity and efficacy of drugs. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.Novel drug delivery system classified in to different types based on the diffusion types.Drug Delivery Carriers show great promise as drug delivery systems.Drug delivery may be either active or passive process. These are designed to target the site specific region, in order to achieve desired therapeutic effect, thereby reducing the side or toxic effects. NTTD Increases the efficacy of the drug and decrease side effects. The global market for drug delivery systems is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2021.
  • Track 3-1. Sustained Drug Delivery Systems
  • Track 3-2. Intracellular Drug Delivery Systems
  • Track 3-3. Magnetically Induced Drug Delivery System
  • Track 3-4. Transdermal Drug Delivery Systems
  • Track 3-5. Dendrimer Drug Delivery Systems
  • Track 3-6. Nano particulate Drug Delivery Systems
  • Track 3-7. Targeted Drug Delivery Systems
  • Track 3-8. Trans mucosal Drug Delivery Systems
  • Track 3-9. Modified Drug Delivery Systems
  • Track 3-10. Local Drug Delivery Systems
  • Track 3-11. Blood Brain Barrier Delivery Systems
Pharmaceutical Nanotechnology has wide applications like nanoemulsions enhancing the absorption of a drug in particular site, increasing the microbial stability of product, to develop the molecules as tracer maker in identifying the toxic materials. A large number of nanosystems have been found in pharmacy field today are liposomes, metallic nanoparticles, polymeric nanoparticles, carbon nanotubes, quantum dots, nanofibres etc. It provides opportunities to improve materials, medical devices and help to develop new technologies where existing and more conventional technologies may be reaching their limits.
  • Track 4-1. Nanotechnology in Drug Delivery
  • Track 4-2. Nanoparticles
  • Track 4-3. Design of Nanodrugs
  • Track 4-4. Pharmaceutical Nanotechnology based Systems
  • Track 4-5. Nanotechnology for Targeted siRNA Delivery
  • Track 4-6. Future aspects of Pharmaceutical Nanotechnology
  • Track 4-7. Silk fibroin nanoparticle
  • Track 4-8. Coated Gold Nanoparticles
  • Track 4-9. Nanomedicine
  • Track 4-10. Cancer Targeting
  • Track 4-11. Nanoliposome
  • Track 4-12. Nanomedicines in Theranostics
  • Track 4-13. Challenges to Pharmaceutical Nanotechnology
  • Track 4-14. Cellular and Sub cellular Nanotechnology
  • Track 4-15. Advancement In Nanotechnology
Smart drug delivery system (SDDS) is the multi targeted, pH responsive, Stimuli sensitive delivery systems in which delivering the medication to a patient in a manner that increases the concentration of the medication in some parts of the body. Smart drug delivery systems are the future and developing effective delivery systems. Nanotechnology based smart drug delivery systems are proved efficient in diagnosis and treatment of various diseases.
  • Track 5-1. Mucosal Drug Delivery System
  • Track 5-2. Sonophoresis Drug Delivery System
  • Track 5-3. Insitu Drug Delivery
  • Track 5-4. Micelle Drug Delivery
  • Track 5-5. Emulgel Drug Delivery
  • Track 5-6. Microencapsulation Process
  • Track 5-7. Delivery through Versatile polymers
  • Track 5-8. Novel pharmaceutical ingredients
  • Track 5-9. Activation Modulated Drug Delivery System
  • Track 5-10. Protein and Peptide Drug Delivery
  • Track 5-11. Microsponge Drug Delivery System
  • Track 5-12. Lymphoid Drug Delivery System
Drug delivery devices are specialized tools for the delivery of a drug or therapeutic agent via a specific route of administration. Such devices are used as part of one or more medical treatments. Many in the industry have long felt overly burdened by what they consider to be an unnecessarily complex approval process. Critics claim it impedes innovation and delays the availability of better health care. To change that perception, the FDA last year announced $40 million to a new Medical Device Innovation Consortium (MDIC) charged with simplifying the process of designing and testing new technologies. With input from industry, government, and other nonprofit organizations, public-private MDIC will prioritize the regulatory science needs of the medical device community and fund projects to streamline the process. Current research on femtosecond laser microfabrication of fluidic devices is introduced to present their research to elaborate.
  • Track 6-1. Routes of Drug Delivery
  • Track 6-2. Drug-Device Combinations
  • Track 6-3. Inhalation drug delivery devices
  • Track 6-4. Biopolymers in Drug Delivery
Proteins and peptides are the most abundant components of biological systems. Peptides and proteins are attracting increasing in attention as therapeutics. Transdermal peptide therapeutics avoids the problems with GI tract. The clinical peptide therapeutic pipeline composed of 128 peptide therapeutics. The recent advances in the peptide and protein drug delivery systems are PEGylation and Depo-foam technology. Cell-penetrating peptides (CPPs) act as cargo carriers and constitute a current hotspot in medical research. CPPs to transport hydrophilic macromolecules into cells, thus, assist to execute biological functions. CPPs do not destroy the integrity of the cell membranes, and are considered more efficient and safe and providing new avenues for research and applications in life sciences.
A biomaterial is any substance other than drug or combination of substances, synthetic or natural in origin. It can be used for any period of time or as a part of a system which treat diagnosis or replace any part of the body. It is used to prepare biomedical device or bio implant that is used to treat, replace or augment any tissue or organ in the body. Biomaterials are also used every day in dental applications, surgery, and drug delivery. A biomaterial is also an autograft, allograft used as a transplant material. ECM and ECM-like materials, or ECM-synthetic polymer hybrids, used as biomaterials in the field of regenerative medicine.
  • Track 8-1. Bioinformatics
  • Track 8-2. Bioimaging
  • Track 8-3. Biomechanics and Biomaterials
  • Track 8-4. Cellular Engineering
Nucleic acids science and technologies experience tremendous progress and changes. This Nucleic Acid Based Drug Delivery track will feature prominent experts discussing latest advances in nucleic acids, industrial pharmacy, pharmaceutical design, drug targeting, anticancer drug development , Nano pharmaceutics, research and development: TNA for treating cancer and viral diseases in the near future for drug delivery includes novel Rnai-Based Therapy, advances in siRNA delivery, oligonucleotide drug delivery, viral gene therapy and Artificial microRNAs, non-coding RNA (miRNA, piRNA, lncRNA, and lincRNA) this architect session to play an important role in the fields of cancer targeting and pharmaceutical nanotechnology.
  • Track 9-1. Nucleic acids, industrial pharmacy
  • Track 9-2. Pharmaceutical design
  • Track 9-3. Drug targeting
  • Track 9-4. Anticancer drug development
  • Track 9-5. Nano pharmaceutics
  • Track 9-6. Research and development TNA for treating cancer and viral diseases
Nanomedicine is simply the nanotechnology applications in a healthcare setting and the majority of benefits that have already been seen involve the use of nanoparticles to improve the behaviour of drug substances and in drug delivery. Today, nanomedicines are used globally to improve the treatments and lives of patients suffering from a range of disorders including ovarian and breast cancer, kidney disease, fungal infections, elevated cholesterol, menopausal symptoms, multiple sclerosis, chronic pain, asthma and emphysema. Nanomedicine has the potential to develop radical new therapies based on an unprecedented control over both intracellular processes and the extracellular environment at the nanometer scale. To create precise solutions for intricate medical challenges in the area of wound healing, tissue regeneration and mitochondrial disease physical scientists, medical doctors, and industrial partners, work closely in the Radboud Nanomedicine Alliance.
  • Track 10-1. Nanomedicine for CNS
  • Track 10-2. Novel Drugs to Nano Drugs
  • Track 10-3. Nanomedicine for Gastrointestinal Tract GI Diseases
  • Track 10-4. Nanomedicine for blood disorders and Lung Diseases
  • Track 10-5. Nanomedicine for Cardiovascular Diseases
  • Track 10-6. Nanodrugs for Herbal medicines and Cosmetics
  • Track 10-7. Nanomedicine for other disease
  • Track 10-8. Future aspects of Nanomedicine
Vaccine is a material that can produce an immunologically mediated resistance to a disease. Vaccines are prepared by killed or attenuated microorganisms. Vaccine drug delivery systems are getting popularity due to benefits they offer. Needle free technology, edible vaccines used for oral delivery of vaccines. Reason behind development of vaccines as controlled drug delivery systems are: 1) Immunization failure with conventional immunization regimen, 2) Allow for the incorporation of doses of antigens so that booster doses are no longer necessary as antigens are released slowly in a controlled manner 3) Control the spatial and temporal presentation of antigens to the immune system there by promoting their targeting straight to the immune cells.
Transdermal Drug Delivery system is an integral part of novel drug delivery system. Drugs having long pharmacokinetic half-lives are considered to be Unsuitable for transdermal application. By the increased number of marketing authorization applications together with recent scientific developments for transdermal patches, the need for clear guidance on specific requirements for this dosage form increased. The emergence of technological innovations in transdermal patches is expected to provide the market with lucrative growth opportunities over the coming years. Transdermal Drug Delivery system was valued at $32,516 million in 2016, and is estimated to reach $61,689 million by 2023, growing at a CAGR of 9.5%.
  • Track 12-1. Novel Delivery Systems for Transdermal drug delivery
  • Track 12-2. Computational Modeling of Transdermal and Intradermal Delivery
  • Track 12-3. Applications and Advances of Transdermal and Intradermal Drug Delivery
Wearable Drug Delivery is changing the world of drug delivery and preventing the patients from continuous bulk ambulatory devices .Wearable” drug delivery device delivers insulin to the wearer. These are developed for dosing a range of drugs such as hormones, analgesics, anti-hypertensives. Large doses 5ml to 50 ml can be comfortably be self-administered by the patient at home by using the Wearable Drug Delivery devices. The life cycle of the product can also be increases. Wearable technology speeds the Formulation and development.
  • Track 13-1. Perspectives on Wearable Drug Delivery
  • Track 13-2. Wearable Drug Delivery System
  • Track 13-3. Wearable smart dose injectors
  • Track 13-4. Design and Operational Challenges of Wearable Drug Delivery Systems
Development of a new pharmaceutical product requires at least 15 years because of changes in the regulatory. Regulatory Affairs Department acts as the interface between the pharmaceutical company and the regulatory agencies across the world. Regulatory authorities act a vital role for approval of generics. Regulatory Affairs contributes essentially to the overall success of drug development, both at early pre-marketing stages and at all times post-marketing. Regulatory Affairs professionals can play a key role in guiding drug development strategy in an increasingly global environment. North America and Europe contribute about 57.0% of global pharmaceutical sales. The global regulatory affairs outsourcing market size was valued at USD 4.53 billion in 2016 and is expected to grow at a CAGR of 11.9% over the forecast period.
  • Track 14-1. Drug Safety
  • Track 14-2. Regulatory Strategies and developments for new drugs
  • Track 14-3. Regulatory Requirements for Pharmaceuticals
  • Track 14-4. Pharmacoeconomics and outcomes research
  • Track 14-5. Biosimilars
Opportunities and challenges for Drug Delivery Market in the Pharmaceutical analytical Market to forecasts for Drug Delivery Market in the global Pharmaceutical companies from 2009 to 2025. Sessions includes solid pharmaceutical Drug Dosage Formulations, drug bioavailability, Tumor targeting, Tumor Biomarkers, coating materials. The key geographies including the US, Europe, Japan and Emerging Hotspots such as India, Singapore and China Technology trends in Drug Delivery Market that shape the industry Qualitative analysis of the market drivers, barriers, future outlook and challenges for the Drug Delivery Market Analysis of competitive landscape and the leading market players. By focusing on Major challenges in Drug Delivery in the drug-delivery technology market, There is an increasing demand for effective and, ideally, non-invasive drug-delivery methods. This is especially the case for the biopharmaceutical sector, which has experienced an overwhelming growth due to advances in biotechnology. In 2009, over $12 billion were invested in biologics / biotechnology research and development (RandD), representing a 26% share in the total RandD expenditure. A recent report by the Pharmaceutical Research and Manufacturers of America (PhRMA) states that in 2015 there were 901 biological in development, targeting more than 100 diseases.
The global market for Business Development of Drug Delivery Technology in 2010 was $131.6 billion and is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2016. The U.S. constituted approximately 59% of the total drug delivery market in 2010 and was $78 billion. It is forecast to reach nearly $103 billion in 2016 at a CAGR of 4.7%. Europe contributed about 27% of the total drug delivery market in 2010 and was $36 billion and is expected to grow to $49 billion by 2016 at a CAGR of 5.6% for 2013, Drug Delivery Global market reached $150.3 billion, according to BCC research. This was an increase from $142 billion the previous year. Given its predicted annual growth the market represents a considerable business opportunity, which has been reflected in the increasing number of drug delivery specialists. Consistent quality and competitive costs of product improves Production performance and continuity of supply and Product and technology auditing and due diligence with minimizing Regulatory Issues, quality control, and business development Business opportunities in drug delivery.